Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients (Q45280472)

11 December 2017

title

Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients (English)

1 reference

11 December 2017

1 reference

Matteo Bassetti

1 reference

11 December 2017

Mario Cruciani

1 reference

11 December 2017

Giorgio Gatti

1 reference

11 December 2017

Emanuela Vaccher

1 reference

11 December 2017

Giampiero Di Gennaro

1 reference

11 December 2017

Roberta Cinelli

1 reference

11 December 2017

Umberto Tirelli

1 reference

11 December 2017

Dante Bassetti

1 reference

11 December 2017

language of work or name

English

0 references

publication date

22 February 2005

1 reference

Journal of Antimicrobial Chemotherapy

11 December 2017

1 reference

inferred from page(s)

published in

1 reference

11 December 2017

1 reference

11 December 2017

1 reference

11 December 2017

page(s)

546-549

1 reference

Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Protease inhibitors potentiate chemotherapy-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Drug interactions between antiretroviral drugs and comedicated agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Therapeutic drug monitoring as a tool in treating HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI050

21 January 2018

Identifiers

DOI

10.1093/JAC/DKI050

1 reference

11 December 2017

1 reference